Levels of Immune Marker TREM2 Rise Years Before Alzheimer’s Disease Becomes Apparent

Researchers reported that TREM2 levels rise early on in the progression of Alzheimer’s disease, and that the biomarker might be useful in clinical research to evaluate the benefits of new AD therapies on neuroinflammation, or may one day be a therapeutic target itself.

Levels of an immune cell receptor called TREM2 were found to increase early on in the progression of Alzheimer’s disease (AD),